178 related articles for article (PubMed ID: 32632141)
1. BRN2 expression increases anoikis resistance in melanoma.
Pierce CJ; Simmons JL; Broit N; Karunarathne D; Ng MF; Boyle GM
Oncogenesis; 2020 Jul; 9(7):64. PubMed ID: 32632141
[TBL] [Abstract][Full Text] [Related]
2. MITF and BRN2 contribute to metastatic growth after dissemination of melanoma.
Simmons JL; Pierce CJ; Al-Ejeh F; Boyle GM
Sci Rep; 2017 Sep; 7(1):10909. PubMed ID: 28883623
[TBL] [Abstract][Full Text] [Related]
3. Inverse expression states of the BRN2 and MITF transcription factors in melanoma spheres and tumour xenografts regulate the NOTCH pathway.
Thurber AE; Douglas G; Sturm EC; Zabierowski SE; Smit DJ; Ramakrishnan SN; Hacker E; Leonard JH; Herlyn M; Sturm RA
Oncogene; 2011 Jul; 30(27):3036-48. PubMed ID: 21358674
[TBL] [Abstract][Full Text] [Related]
4. BRN2 is a non-canonical melanoma tumor-suppressor.
Hamm M; Sohier P; Petit V; Raymond JH; Delmas V; Le Coz M; Gesbert F; Kenny C; Aktary Z; Pouteaux M; Rambow F; Sarasin A; Charoenchon N; Bellacosa A; Sanchez-Del-Campo L; Mosteo L; Lauss M; Meijer D; Steingrimsson E; Jönsson GB; Cornell RA; Davidson I; Goding CR; Larue L
Nat Commun; 2021 Jun; 12(1):3707. PubMed ID: 34140478
[TBL] [Abstract][Full Text] [Related]
5. Peptide L13S Derived from the BRN2 POU Domain Reduces Metastasis
Cesar MCM; Mortara RA; Souza VS; Alves VRG; Paschoalin T; Soufen MA; DE Freitas GM; DA Cunha FFM; Tada DB; Dobroff AS; Arruda DC
Anticancer Res; 2024 Jan; 44(1):71-84. PubMed ID: 38160013
[TBL] [Abstract][Full Text] [Related]
6. BRN2, a POUerful driver of melanoma phenotype switching and metastasis.
Fane ME; Chhabra Y; Smith AG; Sturm RA
Pigment Cell Melanoma Res; 2019 Jan; 32(1):9-24. PubMed ID: 29781575
[TBL] [Abstract][Full Text] [Related]
7. BRN2 suppresses apoptosis, reprograms DNA damage repair, and is associated with a high somatic mutation burden in melanoma.
Herbert K; Binet R; Lambert JP; Louphrasitthiphol P; Kalkavan H; Sesma-Sanz L; Robles-Espinoza CD; Sarkar S; Suer E; Andrews S; Chauhan J; Roberts ND; Middleton MR; Gingras AC; Masson JY; Larue L; Falletta P; Goding CR
Genes Dev; 2019 Mar; 33(5-6):310-332. PubMed ID: 30804224
[TBL] [Abstract][Full Text] [Related]
8. In silico studies of the interaction between BRN2 protein and MORE DNA.
do Vale Coelho IE; Arruda DC; Taranto AG
J Mol Model; 2016 Sep; 22(9):228. PubMed ID: 27568376
[TBL] [Abstract][Full Text] [Related]
9. NFIB Mediates BRN2 Driven Melanoma Cell Migration and Invasion Through Regulation of EZH2 and MITF.
Fane ME; Chhabra Y; Hollingsworth DEJ; Simmons JL; Spoerri L; Oh TG; Chauhan J; Chin T; Harris L; Harvey TJ; Muscat GEO; Goding CR; Sturm RA; Haass NK; Boyle GM; Piper M; Smith AG
EBioMedicine; 2017 Feb; 16():63-75. PubMed ID: 28119061
[TBL] [Abstract][Full Text] [Related]
10. Phosphorylation of BRN2 modulates its interaction with the Pax3 promoter to control melanocyte migration and proliferation.
Berlin I; Denat L; Steunou AL; Puig I; Champeval D; Colombo S; Roberts K; Bonvin E; Bourgeois Y; Davidson I; Delmas V; Nieto L; Goding CR; Larue L
Mol Cell Biol; 2012 Apr; 32(7):1237-47. PubMed ID: 22290434
[TBL] [Abstract][Full Text] [Related]
11. SOX9 and SOX10 but not BRN2 are required for nestin expression in human melanoma cells.
Flammiger A; Besch R; Cook AL; Maier T; Sturm RA; Berking C
J Invest Dermatol; 2009 Apr; 129(4):945-53. PubMed ID: 18923447
[TBL] [Abstract][Full Text] [Related]
12. Bi-allelic Loss of CDKN2A Initiates Melanoma Invasion via BRN2 Activation.
Zeng H; Jorapur A; Shain AH; Lang UE; Torres R; Zhang Y; McNeal AS; Botton T; Lin J; Donne M; Bastian IN; Yu R; North JP; Pincus L; Ruben BS; Joseph NM; Yeh I; Bastian BC; Judson RL
Cancer Cell; 2018 Jul; 34(1):56-68.e9. PubMed ID: 29990501
[TBL] [Abstract][Full Text] [Related]
13. BRN2 and MITF together impact AXL expression in melanoma.
Simmons JL; Neuendorf HM; Boyle GM
Exp Dermatol; 2022 Jan; 31(1):89-93. PubMed ID: 33119145
[TBL] [Abstract][Full Text] [Related]
14. Peptide R18H from BRN2 Transcription Factor POU Domain Displays Antitumor Activity In Vitro and In Vivo and Induces Apoptosis in B16F10-Nex2 Cells.
da Cunha FFM; Mugnol KCU; de Melo FM; Nascimento MVSQ; de Azevedo RA; Santos RTS; Magalhães JA; Miguel DC; Tada DB; Mortara RA; Travassos LR; Arruda DC
Anticancer Agents Med Chem; 2019; 19(3):389-401. PubMed ID: 30417795
[TBL] [Abstract][Full Text] [Related]
15. Reciprocal Regulation of BRN2 and NOTCH1/2 Signaling Synergistically Drives Melanoma Cell Migration and Invasion.
Fane ME; Chhabra Y; Spoerri L; Simmons JL; Ludwig R; Bonvin E; Goding CR; Sturm RA; Boyle GM; Haass NK; Piper M; Smith AG
J Invest Dermatol; 2022 Jul; 142(7):1845-1857. PubMed ID: 34958806
[TBL] [Abstract][Full Text] [Related]
16. YAP activation in melanoma contributes to anoikis resistance and metastasis.
Zhao B; Xie J; Zhou X; Zhang L; Cheng X; Liang C
Exp Biol Med (Maywood); 2021 Apr; 246(8):888-896. PubMed ID: 33307801
[TBL] [Abstract][Full Text] [Related]
17. Critical role of STAT3 in melanoma metastasis through anoikis resistance.
Fofaria NM; Srivastava SK
Oncotarget; 2014 Aug; 5(16):7051-64. PubMed ID: 25216522
[TBL] [Abstract][Full Text] [Related]
18. Timp1 interacts with beta-1 integrin and CD63 along melanoma genesis and confers anoikis resistance by activating PI3-K signaling pathway independently of Akt phosphorylation.
Toricelli M; Melo FH; Peres GB; Silva DC; Jasiulionis MG
Mol Cancer; 2013 Mar; 12():22. PubMed ID: 23522389
[TBL] [Abstract][Full Text] [Related]
19. A PAX3/BRN2 rheostat controls the dynamics of BRAF mediated MITF regulation in MITF
Smith MP; Rana S; Ferguson J; Rowling EJ; Flaherty KT; Wargo JA; Marais R; Wellbrock C
Pigment Cell Melanoma Res; 2019 Mar; 32(2):280-291. PubMed ID: 30277012
[TBL] [Abstract][Full Text] [Related]
20. ERK-regulated αB-crystallin induction by matrix detachment inhibits anoikis and promotes lung metastasis in vivo.
Malin D; Strekalova E; Petrovic V; Rajanala H; Sharma B; Ugolkov A; Gradishar WJ; Cryns VL
Oncogene; 2015 Nov; 34(45):5626-34. PubMed ID: 25684139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
